Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Human CellExp HVEM/TNFRSF14, human recombinant protein
TNFRSF14, ATAR, HVEA, HVEM, LIGHTR, TR2, Tumor necrosis factor receptor superfamily member 14, Herpe
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q92956 |
|---|---|
| Calculated MW | This protein is a disulfide-linked homodimeric protein after removal of the signal peptide. The reduced monomer consists of 413 amino. rhHVEM-Fc, fused with the Fc region of human IgG1 at the C-terminus and has a calculated MW of 45.4 kDa expressed. Protein migrates as 50-60 kDa in reduced SDS-PAGE resulting from glycosylation. |
| Gene ID | 8764 |
|---|---|
| Gene Symbol | TNFRSF14 |
| Other Names | TNFRSF14, ATAR, HVEA, HVEM, LIGHTR, TR2, Tumor necrosis factor receptor superfamily member 14, Herpesvirus entry mediator. |
| Gene Source | Human |
| Source | HEK293 cells |
| Assay&Purity | SDS-PAGE; ≥95% |
| Assay2&Purity2 | N/A; |
| Recombinant | Yes |
| Results | Measured by its ability to inhibit TNF-beta-mediated cytotoxicity using L929 Mouse fibrosarcoma cells. The ED50 for this effect is typically 2.5-10 µg/ml in the presence of 1 ng/ml of recombinant human TNF-beta. |
| Target/Specificity | HVEM/TNFRSF14 |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
| Format | Lyophilized |
| Storage | -20°C; Lyophilized from 0.22 µm filtered solution in 50 mM tris, 100 mM glycine, pH 7.0. Normally Mannitol or Trehalose is added as protectants before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Herpesvirus entry mediator (HVEM), also known as TNFRSF14, TR2 (TNF receptor like molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFβ (lymphotoxin α) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTβR, the receptor for lymphotoxin αβ heterotrimer. The role of the HVEM LIGHT /LTβ receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.
References
Montgomery R.I.,et al.Cell 87:427-436(1996).
Kwon B.S.,et al.J. Biol. Chem. 272:14272-14276(1997).
Zhang W.,et al.Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
Struyf F.,et al.J. Infect. Dis. 185:36-44(2002).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
